Product Description
Rimegepant is used to prevent and treat the symptoms of migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound or light). Rimegepant is in a class of medications called calcitonin gene-related peptide receptor antagonists.
Mechanisms of Action: CGRP Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Belgium | Chile | Croatia | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Lithuania | Luxembourg | Mexico | Norway | Philippines | Poland | Portugal | Romania | Slovakia | Spain | Sweden | United Arab Emirates | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, Czech Republic, Finland, France, Hungary, India, Italy, Japan, Mexico, Poland, Slovakia, Spain, Sweden, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 26
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Migraine Disorders|Migraine with Aura|Migraine without Aura|Nasal Polyposis|Sinusitis
Phase 2: Irritable Bowel Syndrome|Psoriasis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT06221111 | P2 |
Completed |
Irritable Bowel Syndrome |
2025-05-30 |
12% |
2025-06-06 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
| NCT04629950 | P2 |
Completed |
Psoriasis |
2024-08-20 |
50% |
2025-01-29 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| C4951003-BHV3000-312 | P3 |
Recruiting |
Migraine without Aura|Migraine Disorders|Migraine with Aura |
2025-09-01 |
41% |
2025-05-02 |
Treatments |
| C4951019 | P3 |
Active, not recruiting |
Migraine Disorders |
2025-08-24 |
31% |
2025-06-07 |
Patient Enrollment|Primary Endpoints |
| BHV3000-316 | P3 |
Completed |
Sinusitis|Nasal Polyposis |
2024-03-11 |
20% |
2024-06-28 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| BHV3000-312 | P3 |
Recruiting |
Migraine Disorders |
2030-07-31 |
41% |
2025-05-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| jRCT2031250041 | P3 |
Not yet recruiting |
Migraine Disorders |
2027-04-30 |
|||
| Acute Treatment | P3 |
Recruiting |
Migraine Disorders |
2029-01-09 |
85% |
2024-11-14 |
Primary Endpoints |
| jRCT2051240163 | P3 |
Not yet recruiting |
Migraine Disorders |
2028-07-11 |
|||
| C4951013 | P3 |
Not yet recruiting |
Migraine Disorders |
2027-12-02 |
2025-05-02 |
Treatments |
|
| C4951009 | P3 |
Recruiting |
Migraine without Aura|Migraine with Aura|Migraine Disorders |
2027-06-09 |
2025-05-02 |
Treatments |
|
| jRCT2031240036 | P3 |
Recruiting |
Migraine Disorders |
2027-04-29 |
|||
| BHV3000-315 | P3 |
Recruiting |
Migraine Disorders |
2027-04-29 |
32% |
2025-03-27 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| jRCT2031230579 | P3 |
Not yet recruiting |
Migraine Disorders |
2027-01-31 |
|||
| C4951063 | P3 |
Recruiting |
Migraine Disorders |
2026-11-29 |
65% |
2025-03-28 |
Primary Endpoints |
| C4951013 | P3 |
Recruiting |
Migraine Disorders |
2026-10-08 |
62% |
2025-06-07 |
Primary Endpoints |
| jRCT2031220237 | P3 |
Recruiting |
Migraine Disorders |
2025-03-31 |
|||
| C4951002 | P3 |
Recruiting |
Migraine without Aura|Migraine with Aura|Migraine Disorders |
2025-02-15 |
85% |
2025-05-02 |
Treatments |
| Japan Only | P3 |
Completed |
Migraine Disorders |
2024-11-30 |
38% |
2025-01-09 |
|
| 2020-003761-18 | P3 |
Active, not recruiting |
Migraine Disorders|Migraine with Aura|Migraine without Aura |
2024-09-13 |
2022-03-13 |
Treatments |
|
| jRCT2031220236 | P3 |
Recruiting |
Migraine Disorders |
2024-06-30 |
|||
| BHV3000-318 | P3 |
Completed |
Migraine Disorders |
2024-02-06 |
38% |
2024-04-27 |
Primary Endpoints|Study Completion Date|Treatments |
| CTR20220692 | P3 |
Completed |
Migraine Disorders |
2024-02-06 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| Japan Only | P3 |
Completed |
Migraine Disorders |
2024-01-19 |
27% |
2025-02-12 |
Patient Enrollment|Primary Endpoints|Treatments |
| 2020-003517-35 | P3 |
Active, not recruiting |
Migraine with Aura|Migraine Disorders|Migraine without Aura |
2023-11-05 |
85% |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/19/2025 |
News Article |
Lundbeck Advances Leadership in Migraine With New Data at the American Headache Society 67th Annual Scientific Meeting |
|
05/16/2024 |
News Article |
Pharmaceutical Contract Packaging Market Size Expected to Reach USD 36.11 Bn by 2032 |
|
04/04/2024 |
News Article |
NURTEC ODT® is Now Available in Canada for the Treatment of Acute Migraine |
|
03/11/2024 |
News Article |
American Headache Society Publishes Updated Guidance on Migraine Preventive Therapy |